Omega-3 therapeutic supplementation in a patient with metastatic adenocarcinoma of the pancreas with muscle mass depletion

2017 ◽  
Vol 71 (6) ◽  
pp. 795-797 ◽  
Author(s):  
R Ramalho ◽  
P Ramalho ◽  
N Couto ◽  
P Pereira
Keyword(s):  
Muscle Mass ◽  
Metastatic Adenocarcinoma ◽  
Omega 3 ◽  
Mass Depletion ◽  
Adenocarcinoma Of The Pancreas

scholarly journals A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas

2019 ◽  
Vol 15 (28) ◽  
pp. 3189-3196 ◽  
Author(s):  
Philip A Philip ◽  
Marc E Buyse ◽  
Angela T Alistar ◽  
Caio MSPR Lima ◽  
Sanjeev Luther ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Clinical Trial ◽  
Response Rate ◽  
Objective Response ◽  
Phase Iii ◽  
Metastatic Adenocarcinoma ◽  
Open Label ◽  
Clinical Trial Registration ◽  
Entry Points ◽  
Adenocarcinoma Of The Pancreas

Devimistat (CPI-613®) is a novel lipoate analog that inhibits the tricarboxcylic acid cycle at two key carbon entry points. Through its inhibition of pyruvate dehydrogenase and a-ketoglutarate dehydrogenase complexes, devimistat inhibits the entry of glucose and glutamine derived carbons, respectively. Pancreatic cancer is dependent on mitochondrial function for enhanced survival and aggressiveness. In a Phase I study of modified FOLFIRINOX, in combination with devimistat for metastatic pancreatic cancer patients, there was a 61% objective response rate including a 17% complete response rate. This report outlines the rationale and design of the AVENGER 500 study, a Phase III clinical trial of devimistat in combination with modified FOLFIRINOX compared with FOLFIRINOX alone for patients with previously untreated metastatic adenocarcinoma of the pancreas. Clinical trial registration: NCT03504423

scholarly journals Analysis of fat and muscle mass in patients with inflammatory bowel disease during remission and active phase

2008 ◽  
Vol 101 (5) ◽  
pp. 676-679 ◽  
Author(s):  
Raquel Rocha ◽  
Genoile Oliveira Santana ◽  
Neogélia Almeida ◽  
Andre Castro Lyra
Keyword(s):  
Inflammatory Bowel Disease ◽  
Body Composition ◽  
Crohn’S Disease ◽  
Disease Activity ◽  
Muscle Mass ◽  
Fat Mass ◽  
Bowel Disease ◽  
Active Phase ◽  
Mass Depletion ◽  
Inflammatory Bowel

Inflammatory bowel disease (IBD) is often associated with malnutrition. The aim of this study was to compare the body composition of outpatients with IBD during remission and active phase. In order to evaluate disease activity we used Crohn's Disease Activity Index for Crohn's disease (CD) patients and Lichtiger's Index for ulcerative colitis (UC) patients. All patients underwent the analysis of BMI, arm muscle area (AMA) and triceps plus subscapula skinfold thickness (TST+SST) to identify total, muscle and fat mass, respectively. In total 102 patients were evaluated (CD,n50; UC,n52) and the majority was young women. Malnutrition according to BMI was found in 14·0 % of patients with CD and 5·7 % of UC patients. Muscle mass depletion was detected in more than half of the CD and UC patients. The BMI, TST+SST and AMA values were lower in the active phase only in CD patients (P < 0·05). Fat mass depletion was associated with active phase in both CD and UC patients. Body composition parameters obtained using BMI, TST+SST and AMA were not correlated with the presence of fistula in CD patients (P>0·05). In conclusion, patients without signs of malnutrition had fat mass depletion especially in the active phase and muscle mass depletion occurred both in CD and UC patients.

Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas

1995 ◽  
Vol 13 (4) ◽  
pp. 347-354 ◽  
Author(s):  
Richard M. Scher ◽  
Richard Kosierowski ◽  
Charles Lusch ◽  
Roland Alexander ◽  
Stephen Fox ◽  
...  
Keyword(s):  
Phase Ii ◽  
Phase Ii Trial ◽  
Metastatic Adenocarcinoma ◽  
Adenocarcinoma Of The Pancreas
Sign in / Sign up

Export Citation Format

Share Document